Claro Advisors LLC Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Claro Advisors LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,172 shares of the biopharmaceutical company’s stock after acquiring an additional 2,617 shares during the period. Claro Advisors LLC’s holdings in Gilead Sciences were worth $1,032,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of GILD. Avior Wealth Management LLC raised its holdings in shares of Gilead Sciences by 1.2% in the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares during the last quarter. Concord Asset Management LLC VA grew its holdings in shares of Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 111 shares in the last quarter. TFB Advisors LLC increased its position in shares of Gilead Sciences by 1.2% during the third quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after acquiring an additional 116 shares during the last quarter. Sumitomo Life Insurance Co. boosted its position in Gilead Sciences by 0.7% in the third quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock worth $1,494,000 after purchasing an additional 117 shares during the last quarter. Finally, FDx Advisors Inc. grew its stake in Gilead Sciences by 2.2% in the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 117 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Mizuho increased their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. The Goldman Sachs Group upped their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Barclays raised their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Finally, Sanford C. Bernstein initiated coverage on Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 453,734 shares of company stock worth $41,902,086 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.1 %

GILD stock traded up $0.09 during midday trading on Monday, hitting $89.97. The company had a trading volume of 3,736,254 shares, compared to its average volume of 5,679,446. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The stock has a market cap of $112.13 billion, a price-to-earnings ratio of 999.67, a PEG ratio of 2.24 and a beta of 0.18. The stock’s 50 day moving average price is $91.94 and its 200 day moving average price is $83.39.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the prior year, the company posted $2.29 EPS. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.